Skip to main content
Clinical Kidney Journal logoLink to Clinical Kidney Journal
. 2021 Aug 13;15(1):60–69. doi: 10.1093/ckj/sfab149

The Indian Chronic Kidney Disease (ICKD) study: baseline characteristics

Vivek Kumar 1,#, Ashok Kumar Yadav 2,#, Jasmine Sethi 3, Arpita Ghosh 4, Manisha Sahay 5, Narayan Prasad 6, Santosh Varughese 7, Sreejith Parameswaran 8, Natarajan Gopalakrishnan 9, Prabhjot Kaur 10, Gopesh K Modi 11, Kajal Kamboj 12, Monica Kundu 13, Vivek Sood 14, Neeraj Inamdar 15, Ajay Jaryal 16, Sanjay Vikrant 17, Saurabh Nayak 18, Shivendra Singh 19, Sishir Gang 20, Seema Baid-Agrawal 21, Vivekanand Jha 22,23,24,
PMCID: PMC8757418  PMID: 35035937

ABSTRACT

Background

Chronic kidney disease (CKD) is an important cause of morbidity and mortality worldwide. There is a lack of information on epidemiology and progression of CKD in low–middle income countries. The Indian Chronic Kidney Disease (ICKD) study aims to identify factors that associate with CKD progression, and development of kidney failure and cardiovascular disease (CVD) in Indian patients with CKD.

Methods

ICKD study is prospective, multicentric cohort study enrolling patients with estimated glomerular filtration rate (eGFR) 15–60 mL/min/1.73 m2, or >60 mL/min/1.73 m2 with proteinuria. Clinical details and biological samples are collected at annual visits. We analysed the baseline characteristics including socio-demographic details, risk factors, disease characteristics and laboratory measurements. In addition, we compared characteristics between urban and rural participants.

Results

A total of 4056 patients have been enrolled up to 31 March 2020. The mean ± SD age was 50.3 ± 11.8 years, 67.2% were males, two-thirds of patients lived in rural areas and the median eGFR was 40 mL/min/1.73 m2. About 87% were hypertensive, 37% had diabetes, 22% had CVD, 6.7% had past history of acute kidney injury and 23% reported prior use of alternative drugs. Diabetic kidney disease, chronic interstitial nephritis (CIN) and CKD-cause unknown (CKDu) were the leading causes. Rural participants had more occupational exposure and tobacco use but lower educational status and income. CIN and unknown categories were leading causes in rural participants.

Conclusions

The ICKD study is the only large cohort study of patients with mild-to-moderate CKD in a lower middle income country. Baseline characteristics of study population reveal differences as compared with other cohorts from high-income countries.

Keywords: alternative drugs, chronic kidney disease, chronic interstitial nephritis, cohort study, rural health, socioeconomic factors

INTRODUCTION

Global Burden of Disease collaboration identifies chronic kidney disease (CKD) as a major contributor to global morbidity and mortality [1]. Between 1990 and 2017, the global all-age prevalence and mortality from CKD increased by 29.3 and 41.5%, respectively [1]. In India, there was a 38% increase in the proportion of deaths attributable to kidney failure between 2001–03 and 2010–13 [2]. CKD is also an important cardiovascular disease (CVD) risk factor, the leading cause of premature deaths and disability-adjusted life years. Opportunities for secondary and tertiary prevention in CKD are often missed in developing countries like India [3]. Patients seek medical attention when they are symptomatic, usually late in the course of disease. CKD only comes to light in earlier stages when kidney function evaluation is done for either other health conditions or, less commonly, for routine screening [4]. When coupled with the fact that the major burden of CKD is concentrated in regions with lower socio-demographic indices [1], it becomes clear that risk factor identification and mitigation strategies in CKD will be globally successful only when the unique challenges of these regions are addressed.

The development and outcomes of CKD are impacted by local factors like aetiological spectrum influenced by local risk factors, genetic differences, socio-demographic variables and access to healthcare resources. Cohort studies in patients with CKD have been established in the USA, Germany, Canada, France, Spain, Japan, Republic of South Korea and China [5–11]. These have allowed compilation of a wealth of scientific data that have informed local research and clinical care priorities, as well as international cooperation and comparisons such as the International Network of CKD cohort studies of the International Society of Nephrology [12–14].

The Indian CKD (ICKD) study [15] is a publicly funded cohort study that aims to explore risk factors for progression of CKD, development of CVD and differences in outcomes based on gender, socio-demographic profile and regions, and quality of life and cost of care in a CKD population representing all parts of India. In the present manuscript, we report baseline characteristics of participants enrolled in the ICKD study.

MATERIALS AND METHODS

Study design and setting

The ICKD study is a multicentric, prospective cohort study of patients with mild-to-moderate CKD in India. Participants are recruited in large nephrology services across 11 centres distributed throughout the country (Supplementary Appendix S1: map showing location of centres across India). The study procedures were developed, harmonized and adapted to ensure comparability of data with other International cohorts of patients with CKD. Expert consultations were held to decide on questions about possible risk factors in CKD perceived to be relevant in local context. The study has a distributed biobank, with a local biobank at each centre and the central one at Post-graduate Institute of Medical Education and Research, Chandigarh. The detailed design and methods of the study have been published [15]. The study has been approved by Ethics Committees at each participating centre.

Study population

Clinically stable adult patients aged between 18 and 70 years with estimated glomerular filtration rate (eGFR) by creatinine-based CKD Epidemiology Collaboration (CKD-EPICr) equation of either 15–60 mL/min/1.73 m2, or >60 mL/min/1.73 m2 and proteinuria (urine protein to creatinine ratio >500 mg/g or albumin to creatinine ratio >300 mg/g or equivalent) were approached for consent and recruitment. Organ transplant recipients, pregnant females or those with malignancy, life expectancy <1 year or on current immunosuppressive drug therapy were excluded.

Study measurements and conduct

Details of socio-demographic status, family history, history of CKD risk factors, CVD, acute kidney injury (AKI), comorbidities, occupation, addictions and treatment details including the use of alternative drugs were recorded (Supplementary Appendix S2: baseline questionnaire, Supplementary data, Table S1: definitions/interpretations used for the present analysis in context of data captured in baseline questionnaire). The responses were either self-reported by participants or captured from the records of previous encounters with the healthcare system. Residence was classified as rural or urban. History of pregnancy-related complications was recorded in the case of females. Participants were questioned about past history of any rapid deterioration in kidney function or requirement of dialysis from which they had recovered. Anthropometric measurements (height, weight and waist/hip ratios) and resting blood pressure (BP) were taken, and quality of life based on Kidney Disease Quality of Life Instrument survey was recorded. Serum, plasma and second-morning spot urine samples were collected and stored at −80°C.

Serum creatinine was measured using assays traceable to isotope dilution mass spectrometry reference standards at participating centres. GFR was estimated using the creatinine-based CKD-EPICr equation. Spot urine protein to creatinine ratio (expressed as mg/g) or semi-quantitative urine albumin testing by dipstick (expressed as trace, 1+, 2+ or >2+) was converted to urine albumin to creatinine ratio (uACR) as described by Sumida et al. [16]. Proposed models adjusted for sex, diabetes and hypertension were used for calculation. Hazardous occupational exposure was recorded as regular exposure to sand, saw, dust, cement, pesticides, other chemicals, animals or need for working barefoot in fields. Household income was defined as net annual income of family from all sources. Medical expenditure included costs incurred on medicines and ancillary expenses (travel, stay, etc.) on account of hospital visits. Physical activity was defined as exercise equivalent to 30 min of brisk walk at least five times every week. Other diseases and comorbidities were diagnosed as per prevailing standards. Patients with a primary diagnosis of hypertension or diabetes and/or on anti-hypertensives or anti-diabetic drugs, respectively, were assigned the respective diagnoses. These diagnoses were either self-reported or physician diagnosed based on review of prescription. CVD was defined as history or previous recorded documentation of heart failure, coronary artery disease, prior revascularization, stroke, peripheral vascular disease or any form of atherosclerotic vascular disease. The causes of CKD in the study population were recorded as chronic glomerulonephritis (CGN), chronic interstitial nephritis (CIN), diabetic kidney disease (DKD), hypertensive nephropathy (HTN), polycystic kidney disease (PKD), unknown or miscellaneous. The cause was recorded by the treating physician based on his/her clinical judgement. Unknown cause was recorded in the absence of any known risk factors that could lead to CKD.

Statistical considerations

Data were cleaned, edited and analysed using Stata statistical software version 14 (Stata Corp LP, College Station, TX, USA). Both descriptive and quantitative analyses were performed showing socio-demographic, clinical and biochemical characteristics of participants. Distribution based on gender has been presented in the study. Characteristics of participants from rural and urban regions were compared.

Data for continuous variables were expressed as mean and standard deviation (SD) or median and interquartile range, as appropriate. In the case of categorical variables, data were presented in terms of count and percentage. All the presented data are based on the available values only and percentages have been calculated from total number of available values. Comparison of baseline characteristics between rural and urban participants has been done by Student's t-test, Mann–Whitney U-test, one way Analysis of variance (ANOVA) or chi-square test as appropriate. Two-sided P < 0.05 were considered significant.

RESULTS

A total of 4056 participants were enrolled in the cohort between 1 April 2016 and 31 March 2020 in Phase I of the study. The socio-demographic characteristics of the participants are shown in Table 1. The average age at recruitment is 50.3 ± 11.8 years, with 67.2% of the population being males. Two-thirds of the population lived in rural areas, and 73% had received some formal education. About 35% were vegetarians. Among those classified as non-vegetarians, the frequency of meat consumption (includes meat, fish and fowl) was 4.5 times every month. About 43% of the study population was physically active, and 7.5% and 18.6% participants were current alcohol and tobacco users, respectively. The median (25–75th percentiles) annual expenditure on medical care was US$286 (84–571), which represented ∼17% of the median total annual household income of US$1680 (1008–4200). Only 32.1% of the participants had any medical insurance. About 83% incurred out-of-pocket expenditure for CKD care. Only 10.6% of the participants admitted to missing scheduled hospital visits or drugs on account of financial constraints.

Table 1.

Socio-demographic characteristics of participants in the study cohort

Characteristic Females (n = 1331) Males (n = 2725) Total (n = 4056) Missing, n (%) P-values
Age, years 49.0 ± 11.6 50.9 ± 11.9 50.3 ± 11.8 0 (0) <0.001
Duration of kidney disease, months 40.8 ± 55.6 37.1 ± 51.6 38.3 ± 53.0 32 (0.8) 0.039
BMI, kg/m2 25.3 (22.1–29.0) 24.0 (21.5–26.7) 24.4 (21.6–27.4) 103 (2.5) <0.001
Waist/hip ratio 1.06 (1.02–1.21) 1.05 (1.01–1.08) 1.05 (1.02–1.09) 964 (23.8) <0.001
Place of residence
 Rural 845 (65.2) 1781 (66.5) 2626 (66.0) 80 (2.0) 0.407
 Urban 452 (34.8) 898 (33.5) 1350 (34.0)
Education
 Illiterate 524 (39.6) 564 (20.8) 1088 (26.9) 18 (0.4) <0.001
 School level education 582 (44.0) 1330 (49.0) 1912 (47.4)
 Went to college 216 (16.4) 822 (30.2) 1038 (25.7)
Occupational exposurea 629 (47.6) 1406 (51.8) 2035 (50.4) 18 (0.4) 0.013
 Sand/dust 228 (17.3) 618 (22.8) 846 (21.0)
 Cement 7 (0.5) 81 (2.98) 88 (2.2)
 Saw dust 34 (2.6) 112 (4.1) 146 (3.6)
 Working barefoot in field 58 (4.4) 204 (7.5) 262 (6.5)
 Pesticide spray 41 (3.1) 186 (6.9) 227 (5.6)
 Others 356 (56.6) 593 (42.2) 949 (46.6)
Current tobacco user 87 (6.6) 660 (24.5) 747 (18.6) 43 (1.1) <0.001
Current alcohol user 1 (0.1) 300 (11.1) 301 (7.5) 43 (1.1) <0.001
Physically active 479 (36.4) 1239 (45.9) 1718 (42.8) 43 (1.1) <0.001
Non-vegetarian diet 830 (63.5) 1771 (66.2) 2601 (65.3) 75 (1.9) 0.090
Access to piped water supply 693 (52.4) 1282 (47.2) 1975 (48.9) 18 (0.4) 0.003
Annual household income (USD) 1680 (840–4200) 1680 (1008–4200) 1680 (1008–4200) 41 (1.0) 0.176
Annual household medical expenditure (USD) 269 (84–571) 302 (84–571) 286 (84–571) 0 (0.0) 0.742
Medical insurance 432 (33.2) 844 (31.5) 1276 (32.1) 77 (1.9) 0.284
Incurred out of pocket medical expenditure 1115 (84.3) 2237 (82.4) 3352 (83.0) 18 (0.4) 0.034
Missed hospital visit/drugs due to financial constraints 135 (10.2) 293 (10.8) 428 (10.6) 18 (0.4) 0.577

Data are presented as mean ± SD, median (25–75th percentile) or n (%).

a

Occupational exposure—has multiple responses.

Clinical characteristics

The most common cause of CKD was DKD (24.9%), followed by CIN and unknown in 23.2 and 19.5%, respectively (Table 2). The mean duration of kidney disease at the time of recruitment into the study was 38.3 ± 53.0 months (Table 1). Family history of hypertension, diabetes mellitus and stroke were recorded in 43.1%, 37.4% and 14%, respectively. In terms of risk factors, 87% were hypertensive and 37.5% had diabetes, whereas 22.9% reported history of using alternative drugs (local or indigenous forms of medicine). History of nephrolithiasis and recurrent urinary tract infections (UTIs) were present in 11.8 and 11%, respectively. About 9% of the participants reported a family history of kidney disease. Prior history suggestive of AKI was recorded in 6.7% of study population. About 33% of females reported adverse outcome events during pregnancy. Only 21.8% of participants had prior CVD. The median (25–75th percentiles) body mass index (BMI) and waist/hip ratio in study population were 24.4 (21.6–27.4) kg/m2 and 1.05 (1.02–1.09), respectively (Table 1).

Table 2.

Clinical characteristics and diagnosis of CKD in the study cohort

Parameter Females (n = 1331) Males (n = 2725) Total (n = 4056) Missing, n (%) P-values
Clinical characteristics
 Hypertension 1130 (86.1) 2357 (87.5) 3487 (87.0) 49 (1.2) 0.240
 Diabetes 473 (36.6) 1012 (37.9) 1485 (37.5) 96 (2.4) 0.436
 CVD 255 (19.4) 621 (23.0) 876 (21.8) 33 (0.8) 0.009
 Renal stone disease 139 (10.5) 335 (12.4) 474 (11.8) 27 (0.7) 0.092
 Recurrent UTI 144 (10.9) 298 (11.0) 442 (10.9) 27 (0.7) 0.940
 Alternative drug use 284 (21.5) 639 (23.5) 923 (22.9) 16 (0.4) 0.150
 Ayurvedic 108 (38.0) 256 (40.0) 364 (39.5)
 Homoeopathic 51 (18.0) 158 (24.7) 209 (22.6)
 Siddha 21 (7.4) 30 (4.7) 51 (5.5)
 Unani 8 (2.8) 5 (0.8) 13 (1.4)
 Others 96 (33.8) 190 (29.8) 286 (31.0)
 NSAID use 251 (19.1) 375 (13.9) 626 (15.6) 43 (1.1) <0.001
 History of AKI 91 (6.9) 177 (6.6) 268 (6.7) 43 (1.1) 0.668
 Required dialysis for AKI 88 (6.7) 143 (5.3) 231 (5.8) 43 (1.1) 0.076
 Underwent renal biopsy 228 (17.3) 458 (17.0) 686 (17.1) 43 (1.1) 0.774
Family history
 Hypertension 525 (43.0) 1088 (43.1) 1613 (43.1) 309 (7.6) 0.141
 Diabetes 475 (39.4) 915 (36.4) 1390 (37.4) 337 (8.3) 0.200
 Kidney disease 127 (9.6) 231 (8.5) 358 (8.9) 30 (0.7) 0.502
  Kidney stones 22 (17.3) 41 (17.7) 63 (17.6)
  Dialysis 35 (27.6) 71 (30.7) 106 (29.6)
  Kidney transplant 5 (3.9) 13 (5.6) 18 (5.0)
Cause of CKD
 DKD 333 (25.0) 678 (24.9) 1011 (24.9) 0 (0)
 CIN 319 (24.0) 621 (22.8) 940 (23.2)
 Unknown 243 (18.3) 545 (20.0) 788 (19.5)
 CGN 216 (16.2) 382 (14.0) 598 (14.7) 0.224
 Hypertensive nephrosclerosis 94 (7.1) 226 (8.3) 320 (7.9)
 PKD 49 (3.6) 90 (3.3) 139 (3.4)
 Others 77 (5.8) 183 (6.7) 260 (6.4)

Data are presented as n (%).

NSAID, non-steroidal anti-inflammatory drugs.

Laboratory characteristics

The median (25th–75th percentiles) serum creatinine and eGFR were 1.7 (1.5–2.0) mg/dL and 40.5 (33.7–50.8) mL/min/1.73 m2, respectively (Table 3). Albuminuria (trace or more) by urine dipstick examination was present in 41.4% of the participants, with the calculated uACR being >300 mg/g in 25.5%. Median (25–75th percentiles) haemoglobin (Hb), serum albumin, calcium, inorganic phosphorus and uric acid were 11.8 (10.5–13.2) g/dL, 4.0 (3.5–4.4) g/dL, 9.0 (8.5–9.4) mg/dL, 4.0 (3.3–4.5) mg/dL and 6.4 (5.2–7.6) mg/dL, respectively. About 6.3% and 6.5% of the participants had positive hepatitis B surface antigen and antibodies against hepatitis C virus, respectively (Table 3).

Table 3.

Physical and biochemical characteristics of participants in the study cohort

Characteristic Females (n = 1331) Males (n = 2725) Total (n = 4056) Missing, n (%) P-values
SBP, mmHg 130 (120–141) 130 (120–145) 130 (120–144) 101 (2.5) 0.006
DBP, mmHg 80 (76–90) 80 (78–90) 80 (78–90) 133 (3.3) 0.010
eGFR, mL/min/1.73 m2 36.3 (30.7–45.3) 42.9 (35.7–52.3) 40.5 (33.7–50.8) 0 <0.001
Hb, mg/dL 11.0 (10.0–12.0) 12.4 (11–13.7) 11.8 (10.5–13.2) 143 (3.5) <0.001
Anaemiaa 932 (73.2) 1607 (60.9) 2539 (64.9) 143 (3.5) <0.001
 Mild 329 (25.8) 976 (37.0) 1305 (33.4)
 Moderate 579 (45.5) 597 (22.6) 1176 (30.1)
 Severe 24 (1.9) 34 (1.3) 58 (1.5)
Serum urea, mg/dL 45 (35–56) 45 (34–56) 45 (34–56) 571 (14.1) 0.788
Serum creatinine, mg/dL 1.6 (1.4–1.9) 1.8 (1.5–2.1) 1.7 (1.5–2.0) 0 <0.001
Serum calcium, mg/dL 8.9 (8.4–9.4) 9.0 (8.6–9.5) 9.0 (8.5–9.4) 290 (7.2) 0.0001
Serum inorganic phosphorus, mg/dL 4.1 (3.6–4.6) 3.9 (3.2–4.4) 4.0 (3.3–4.5) 340 (8.4) <0.001
Serum albumin, g/dL 3.9 (3.4–4.2) 4.0 (3.5–4.4) 4.0 (3.5–4.4) 225 (5.6) <0.001
Serum uric acid, mg/dL 6.2 (5.0–7.3) 6.5 (5.4–7.7) 6.4 (5.2–7.6) 842 (20.8) <0.001
Total cholesterol, mg/dL 173 (140–203) 162 (130–198) 166 (133–200) 1538 (37.9) <0.001
Triglycerides, mg/dL 140 (112–180) 136 (108–175) 138 (110–177) 1647 (40.6) 0.202
HbsAg
 Positive 170 (6.2) 255 (6.3) 6 (0.2)
 Negative 750 (56.5) 1614 (59.3) 2364 (58.4) 0.385
 Not available 493 (37.1) 938 (34.3) 1431 (35.3)
Anti-HCV
 Positive 97 (7.3) 167 (6.1) 264 (6.5) 6 (0.2)
 Negative 707 (53.2) 1530 (56.2) 2237 (55.2) 0.132
 Not available 524 (39.5) 1025 (37.7) 1549 (38.3)
uACR, mg/g 45 (12–357) 26 (11–280) 29 (11–304) 272 (6.7) <0.001
 <30 573 (65.9) 1330 (68.4) 1903 (67.6)
 30–299 296 (34.1) 616 (31.7) 912 (32.4)
 300–1000 234 (18.9) 349 (13.70) 583 (15.4)
 >1000 133 (10.8) 251 (9.8) 384 (10.1)

Data are presented as median (25–75th percentile) or n (%).

a

Anaemia was classified as per World Health Organization criteria: mild anaemia, Hb 11.0–11.9 mg/dL for females and 11–12.9 mg/dL for males; moderate anaemia, Hb 8.0–10.9 mg/dL for females and males; and severe anaemia, Hb <8 mg/dL for females and males.

SBP, systolic BP; DBP, diastolic BP; HbA1c, glycosylated Hb; HbsAg, hepatitis B surface antigen; HCV, hepatitis C virus.

Rural–urban comparisons

The socio-demographic, clinical and biochemical characteristics of the rural and urban participants are described in Tables 4 and 5. Age was similar between the groups. Compared with urban participants, those from rural areas had more occupational exposure (54.6% versus 41.5%, P < 0.001), higher tobacco use (20.6% versus 15.1%, P < 0.001), lower level of education (66.8% versus 85.4%, P < 0.001) and non-vegetarian dietary status (68.2% versus 59.9%, P < 0.001). Compared with the urban participants, the median annual household income was almost half in the rural group [US dollars (USD) 1680 versus 3024, P < 0.001]. Fewer patients in the rural regions had medical insurance (27.8% versus 39.8%, P < 0.001). History of use of alternative drugs (26.4% versus 21.4%, P < 0.001), BMI and family history of hypertension or diabetes were more in the urban group. uACR was lower among rural participants (25.5 versus 41.0 mg/g, P = 0.003). CIN and unknown aetiologies were proportionally more in the rural group, whereas DKD and CGN were more in the urban group.

Table 4.

Comparison of socio-demographic and clinical factors between rural and urban subgroups within the study cohort (n = 4056)

Characteristic Rural (n = 2626) Urban (n = 1350) P-value
Age, years 50.5 ± 11.6 49.8 ± 12.1 0.096
BMI, kg/m2 23.8 (21.0–26.8) 25.3 (23.0–28.4) <0.001
Waist/hip ratio 1.05 (1.02–1.10) 1.04 (1.00–1.08) <0.001
Education
 Illiterate 872 (33.21) 197 (14.6) <0.001
 Some schooling 1262 (48.1) 624 (46.2)
 Graduate or above 492 (18.7) 529 (39.2)
Occupational exposurea 1434 (54.6) 560 (41.5) <0.001
  Sand/dust 644 (24.5) 195 (14.4) 0.000
  Cement 64 (2.4) 22 (1.6) 0.097
  Saw dust 123 (4.7) 22 (1.6) 0.000
  Working barefoot in field 238 (9.1) 21 (1.6) 0.000
  Pesticide spray 213 (8.1) 12 (0.9) 0.000
  Others 586 (40.9) 330 (58.9)
Current tobacco user 536 (20.6) 203 (15.1) <0.001
Current alcohol users 193 (7.4) 104 (7.8) 0.691
Physically active 1047 (40.2) 656 (48.9) <0.001
Non-vegetarian diet 1765 (68.2) 805 (59.9) <0.001
Access to piped water supply 1229 (46.8) 710 (52.6) <0.001
Annual household income (USD) 1680 (840–3360) 3024 (1512–6720) <0.001
Annual household medical expenditure (USD) 268.8 (84–521) 336 (84–672) <0.001
Has medical insurance 721 (27.8) 531 (39.8) <0.001
Out-of-pocket medical expenses 2254 (85.8) 1049 (77.7) <0.001
Clinical characteristic
 Hypertension 2207 (85.2) 1226 (91.2) <0.001
 Diabetes 933 (36.3) 530 (40.0) 0.026
 CVD 592 (22.7) 257 (19.2) 0.010
 Renal stone disease 283 (10.8) 183 (13.6) 0.010
 Recurrent UTI 293 (11.2) 144 (10.7) 0.647
 Alternative drug use 561 (21.4) 357 (26.4) <0.001
  Ayurvedic 222 (39.6) 141 (39.5)
  Homoeopathic 135 (24.1) 72 (20.2)
  Siddha 27 (4.8) 24 (6.7)
  Unani 10 (1.8) 3 (0.8)
  Others 167 (29.8) 117 (32.8)
 NSAID use 395 (15.2) 217 (16.2) 0.397
 History of AKI 167 (6.4) 98 (7.3) 0.283
 Required dialysis for AKI 158 (6.1) 70 (5.2) 0.284
 Underwent kidney biopsy 417 (16.0) 264 (19.7) 0.004

Data are presented as mean ± SD, median (25–75th percentile) or n (%).

a

Occupational exposure—has multiple responses.

Table 5.

Physical, biochemical characteristics and diagnosis between rural and urban subgroups within the study cohort (n = 4056)

Characteristic Rural (n = 2626) Urban (n = 1350) P-value
SBP, mmHg 130 (120–143) 130 (120–145) 0.092
DBP, mmHg 80 (78–90) 80 (78–90) 0.981
eGFR, mL/min/1.73 m2 40.0 (33.6–49.7) 42.0 (34.4–52.7) <0.001
Hb, g/dL 11.6 (10.4–13.0) 12.1 (10.8–13.5) <0.001
 Anaemia 1712 (67.8) 771 (58.8) <0.001
 Mild 858 (34.0) 422 (32.2)
 Moderate 814 (32.2) 332 (25.3)
 Severe 40 (1.6) 17 (1.3)
Serum urea, mg/dL 46.0 (35.3–56.0) 43.0 (33.1–53.8) <0.001
Serum creatinine, mg/dL 1.8 (1.5–2.0) 1.7 (1.4–2) <0.001
Serum calcium, mg/dL 9.0 (8.5–9.4) 9.0 (8.5–9.5) 0.982
Serum inorganic phosphorus, mg/dL 4.0 (3.3–4.5) 3.9 (3.3–4.5) 0.978
Serum albumin, g/dL 4.0 (3.5–4.4) 4.0 (3.6–4.4) 0.203
Serum uric acid, mg/dL 6.5 (5.3–7.6) 6.2 (5.1–7.5) 0.024
Total cholesterol, mg/dL 171 (137–202) 156 (128–194) <0.001
Triglycerides, mg/dL 138 (110–176) 137 (107–178) 0.717
HbA1c, % 5.7 (5.1–6.9) 5.6 (5.0–6.6) 0.092
HbsAg-positive status 190 (7.3) 53 (3.9) <0.001
Anti HCV-positive status 195 (7.4) 57 (4.2) <0.001
uACR, mg/g 25.5 (10.7–304.3) 41.0 (11.7–304.3) 0.003
 <30 1255 (69.0) 613 (64.9)
 30–299 563 (30.97) 332 (35.1)
 300–1000 364 (15.0) 206 (16.2)
 >1000 251 (10.3) 123 (9.6)
Cause of CKD <0.001
 DKD 620 (23.6) 370 (27.4)
 CIN 630 (24.0) 283 (21.0)
 Unknown 570 (21.7) 209 (15.5)
 CGN 362 (13.8) 220 (16.3)
 Hypertensive nephrosclerosis 196 (7.5) 123 (9.1)
 PKD 92 (3.5) 45 (3.3)
 Others 156 (5.9) 100 (7.4)

Data presented as mean ± SD, n (%) and median (25–75th percentile).

SBP, systolic BP; DBP, diastolic BP; HbA1c, glycosylated Hb; HbsAg, hepatitis B surface antigen; HCV, hepatitis C virus.

DISCUSSION

This is the first paper to provide a comprehensive description of a nationwide cohort of patients with mild-to-moderate CKD from a developing country like India. The enrolled cohort is representative of the general Indian population in terms of age, sex ratio, representation of rural population, income and education levels, and other socio-economic characteristics according to the National Census [17].

The ICKD cohort is younger as compared with western cohorts (Table 6). It is worth noting that except for the CKD Japan Cohort (CKD-JAC), other Asian cohorts are younger than Western cohorts by 5–20 years. This finding is consistent with previous descriptions of CKD in India [21], and could be due to number of factors such as differential exposure to environmental risk factors, maternal malnutrition leading to development of kidney disease earlier in life, differences in genetic background or delayed recognition leading to faster disease progression [22]. Data from the nationally representative mortality survey of India in the Million Death Study have shown that the highest burden of age-standardized renal deaths was seen in the 45–69 years age group [2]. Approximately two-thirds of participants in our study cohort are males. A similar observation was noted in a multicentric hospital-based registry of patients with CKD in India [21]. This finding contradicts the global observation of a higher prevalence of milder stage CKD among females [20], and might reflect a systematic barrier in presentation to healthcare facilities for females in India, likely due to socio-cultural reasons.

Table 6.

Salient characteristics of major CKD cohort studies in adult population

Characteristic ICKD (n = 4056) CRIC [5, 18] (n = 3612) CKD-JAC [6] (n = 2977) GCKD [19] (n = 5217) CanPREDDICT [7] (n = 2402) C-STRIDE [11] (n = 3168) KNOW-CKD [10] (n = 2238) NEFRONA [8]
Age (years), mean ± SD 50.3 ± 11.8 58.2 ± 11.0 60.8 ± 11.6 60.1 ± 12.0 68.1 ± 12.7 48.2 ± 13.7 53.7 ± 12.2 57.9 ± 12.8
Female sex, % 32.8 46.0 38.0 40.0 37.0 41.0 38.8 42.3
BMI, kg/m2, mean ± SD 24.4 ± 5.8 32.1 ± 7.9 23.5 ± 3.8 29.8 ± 6.0 24.5 ± 3.6 24.6 ± 3.4 28.3 ± 5.2
eGFR, mL/ min/ 1.73 m2, mean ± SD 40.6 ± 17.2 43.4 ± 13.5 28.6 ± 11.8 47.0 ± 17.0 28.0 ± 9.0 50.7 ± 30.0 53.1 ± 30.7 CKD Stage 3–5D
Diabetes, % 37.5 47.0 37.6 35.3 48.0 22.8 33.7 25.7
Hypertension, % 87.0 86.0 81.5 95.0 Not available 77.8 96.1 89.3
CVD, % 21.8 33.0 25.6 32.2 22.0 9.8 6.0 NA
Tobacco use, % 18.6 14.0 16.4 14.9 Not available 38.2 15.7 19.4
Major cause of CKD
  • DKD (24.9)

  • CGN (14.7)

  • HTN (7.9)

  • CIN (23.2)

  • Unknown (19.4)

  • DKD (25.5)

  • HTN (14.5)

  • Other (13.7)

  • Do not know (46.3)

  • DKD (20.6)

  • CGN (31.9)

  • Others (47.5)

  • DKD (15.0)

  • CGN (19.0)

  • Vascular nephropathy (23.0)

  • Interstitial nephropathy (4.6)

  • Unknown [20]

  • DKD (29.0)

  • CGN (11.0)

  • HTN (27.0)

  • PKD (4.0)

  • Others (29.0)

  • DKD (13.9)

  • CGN (60.6)

  • Others (25.6)

  • DKD (23.2)

  • CGN (36.2)

  • HTN (18.3)

  • PKD (16.3)

  • Unknown (6.1)

  • DKD (14.4)

  • CGN (15.6)

  • Vascular nephropathy (19.3)

  • tubulointerstitial (11.7)

  • Unknown (16.7)

The average BMI in our cohort was lower than that reported in the western cohorts [5, 19]. We report a higher proportion of tobacco users, a potentially modifiable CKD risk factor [23] than that in the Chronic Renal Insufficiency Cohort (CRIC), CKD-JAC and German CKD (GCKD) cohorts [5, 6, 19]. Consumption of tobacco, especially in smokeless forms, is a deeply ingrained cultural practice in many parts of India [24]. The Chinese Cohort Study of CKD (C-STRIDE) has reported an even higher prevalence of tobacco use, at 38.2% [11].

Sedentary life style is another modifiable risk factor for CVD and CKD [25]. Just 43% of participants in our cohort reported physical activity corresponding to brisk walk for 30 min on at least 5 days in a week. In the Korean Cohort Study for Outcomes in Patients With CKD (KNOW-CKD) study, physical activity equivalent to that in our cohort was reported by 38.4% of participants [26], and 50% of C-STRIDE participants exercised >3.5 h/week [11]. Taken together, these data show that sedentary habits are common in patients with CKD. As exercise can favourably modulate renal function and control of hypertension in patients with CKD [27], it represents an important intervention that has potential to improve outcomes.

A total of 23% of our cohort participants had used alternative drugs, both before and after the diagnosis of CKD. India has several traditional medical systems that use herbal remedies, but the contribution of these medicines in the development and/or progression of CKD in India is not known. Most of the published data come from China and Taiwan, where higher rates of CKD are documented among consumers of indigenous Chinese herbal medicines [28, 29]. However, recent data from large insurance databases suggest that the associations may be complex and need well-structured exploration [30–33].

Diabetes was the most common cause of CKD (25%). An important finding was the emergence of CIN as the second most common, followed by CKDu. The 2012 Indian CKD Registry report showed DKD to be the designated aetiology in 31%, followed by CKDu at ∼19% and CGN at 14% [21]. CIN and CKDu have an almost identical phenotype and there are no clear criteria that allow distinction between the two. Usually, patients with no apparent risk factors are assigned a diagnosis of ‘unknown’. In the setting of long-standing hypertension (>5 years) without other risk factors, a diagnosis of hypertensive nephrosclerosis was assigned. The aetiological distribution in our cohort is consistent with the recent population-based reports on CKD in India [34–37]. Elucidating the cause in these cases with unknown cause is an important research agenda. The possibility to do additional studies using platform technologies on the biobanked samples holds promise to improve our understanding of potential causes and risk factors.

Only about one-third of the patients enrolled in the study had any medical insurance. Furthermore, >80% of the participants ended up paying the majority of their healthcare costs from their own pocket, which suggests that even when insurance is available, it does not cover all aspects of CKD care.

Almost two-thirds of the ICKD participants were rural, which reflects the population distribution in India. There were some differences between participants from urban and rural areas. Rural participants were less educated, had lower earnings with lower insurance coverage, were more likely to be engaged in manual work and had more hazardous occupational exposure. Tobacco use was also higher among rural participants, while self-reported physical activity was lower in the rural group. Consistent with previous reports, CKDu was identified more frequently in the rural participants. Such findings are being increasingly described from other studies in rural populations in India [38]. Taken together, these data reinforce differences in epidemiology of CKD between urban and rural regions and suggest dominant tubulo-interstitial injury on account of as yet unknown risk factors in rural communities. Elucidation of differences in the characteristics and risk factor profile set the stage for further exploration of causality and development of customized strategies for management and prevention of CKD in rural regions.

Table 6 shows the comparison between selected features of the ICKD cohort and CRIC, GCKD, CKD-JAC, the Canadian study of prediction of death, dialysis and interim cardiovascular events (CanPREDDICT), C-STRIDE, KNOW-CKD and Observatoria Nacional de Aterosclerosis en Nephrologia (NEFRONA). The frequency of CVD was somewhat lower compared with the western cohorts, but greater than in the Asian cohorts. Proportionally higher representation of males, CIN as one of the dominant causes and lack of clinically apparent cause for CKD in one-fifth of participants are other differences in comparison with other cohorts.

While the ICKD cohort offers a unique opportunity to explore the natural history and progression factors for CKD in Indian subjects, a few limitations should be acknowledged. Except for two, all participating centres in our study are public sector hospitals. Therefore, there may be proportionally more representation of patients belonging to lower socio-economic status. Also, our cohort is hospital-based and may not be reflective of CKD in patients who do not present to nephrologists. The latter population might disproportionately include disadvantaged people living in both urban and rural areas. In addition to population differences, variability in practice patterns and access to healthcare services may be responsible for some of the observed differences.

These limitations notwithstanding, the ICKD study is the only large cohort study of patients with mild-to-moderate CKD in a lower middle income country. Its strengths are the pan-India nature, detailed phenotyping, biobanking and rigorous follow-up. The baseline characteristics show unique features that differentiate this population from patients with CKD enrolled in other cohort studies. Given the high and growing disease burden, a relatively rapid rate of progression, the high cost of care and the impact on quality of life [39], data from this study will provide important information to help the national strategy to manage CKD in India. In addition to defining outcomes and finding factors that associate with adverse outcomes in patients with CKD in low-resource settings, the ICKD study offers opportunities for international comparisons to further the goals of the global nephrology community.

SUPPLEMENTARY DATA

Supplementary data are available at ckj online.

FUNDING

This study was funded by Department of Biotechnology, Ministry of Science and Technology grant (Grant No. BT/PR11105/MED/30/1345/2014).

CONFLICT OF INTEREST STATEMENT

V.J. has research grants from Baxter, GlaxoSmithKline and reports consultancy and advisory board honoraria from Baxter Healthcare and AstraZeneca, outside the published work. All other authors reported no conflict of interest.

DATA AVAILABILTY STATEMENT

The study data is not publicly available but can be made available on request.

Supplementary Material

sfab149_Supplementary_Data

Contributor Information

Vivek Kumar, Department of Nephrology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Ashok Kumar Yadav, Department of Experimental Medicine and Biotechnology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Jasmine Sethi, Department of Nephrology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Arpita Ghosh, George Institute for Global Health India, New Delhi, India.

Manisha Sahay, Department of Nephrology, Osmania Medical College, Osmania General Hospital, Hyderabad, India.

Narayan Prasad, Department of Nephrology, Sanjay Gandhi Postgraduate Institute of Medical Science, Lucknow, India.

Santosh Varughese, Department of Nephrology, Christian Medical College, Vellore, India.

Sreejith Parameswaran, Department of Nephrology, Jawaharlal Institute of Postgraduate Medical Education & Research, Pondicherry, India.

Natarajan Gopalakrishnan, Department of Nephrology, Rajiv Gandhi Government General Hospital, Chennai, India.

Prabhjot Kaur, Department of Nephrology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Gopesh K Modi, Samarpan Kidney Institute and Research Center, Bhopal, India.

Kajal Kamboj, Department of Nephrology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Monica Kundu, George Institute for Global Health India, New Delhi, India.

Vivek Sood, Department of Nephrology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Neeraj Inamdar, Department of Nephrology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Ajay Jaryal, Department of Nephrology, Indira Gandhi Medical College, Shimla, India.

Sanjay Vikrant, Department of Nephrology, Indira Gandhi Medical College, Shimla, India.

Saurabh Nayak, Department of Nephrology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Shivendra Singh, Department of Nephrology, Institute of Medical Science, Banaras Hindu University, Varanasi, India.

Sishir Gang, Department of Nephrology, Muljibhai Patel Urological Hospital, Nadiad, India.

Seema Baid-Agrawal, Department of Nephrology and Transplant Center, Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden.

Vivekanand Jha, George Institute for Global Health India, New Delhi, India; School of Public Health, Imperial College, London, UK; Prasanna School of Public Health, Manipal Academy of Higher Education, Manipal, India.

REFERENCES

  • 1. GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet  2020; 395: 709–733 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Dare  AJ, Fu  SH, Patra  J  et al. ; Million Death Study Collaborators. Renal failure deaths and their risk factors in India 2001–13: nationally representative estimates from the Million Death Study. Lancet Glob Health  2017; 5: e89–e95 [DOI] [PubMed] [Google Scholar]
  • 3. Parameswaran  S, Geda  SB, Rathi  M  et al.  Referral pattern of patients with end-stage renal disease at a public sector hospital and its impact on outcome. Natl Med J India  2011; 24: 208–213 [PubMed] [Google Scholar]
  • 4. Jha  V, Ur-Rashid  H, Agarwal  SK  et al. ; ISN South Asia Regional Board. The state of nephrology in South Asia. Kidney Int  2019; 95: 31–37 [DOI] [PubMed] [Google Scholar]
  • 5. Lash  JP, Go  AS, Appel  LJ  et al. ; Chronic Renal Insufficiency Cohort (CRIC) Study Group. Chronic Renal Insufficiency Cohort (CRIC) study: baseline characteristics and associations with kidney function. Clin J Am Soc Nephrol  2009; 4: 1302–1311 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Imai  E, Matsuo  S, Makino  H  et al.  Chronic Kidney Disease Japan Cohort study: baseline characteristics and factors associated with causative diseases and renal function. Clin Exp Nephrol  2010; 14: 558–570 [DOI] [PubMed] [Google Scholar]
  • 7. Levin  A, Rigatto  C, Brendan  B  et al.  Cohort profile: Canadian study of prediction of death, dialysis and interim cardiovascular events (CanPREDDICT). BMC Nephrol  2013; 14: 121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Arroyo  D, Betriu  A, Martinez-Alonso  M  et al.  Observational multicenter study to evaluate the prevalence and prognosis of subclinical atheromatosis in a Spanish chronic kidney disease cohort: baseline data from the NEFRONA study. BMC Nephrol  2014; 15: 168. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Stengel  B, Combe  C, Jacquelinet  C  et al.  The French Chronic Kidney Disease-Renal Epidemiology and Information Network (CKD-REIN) cohort study. Nephrol Dial Transplant  2014; 29: 1500–1507 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Kang  E, Han  M, Kim  H  et al.  Baseline general characteristics of the Korean chronic kidney disease: report from the Korean cohort study for outcomes in patients with chronic kidney disease (KNOW-CKD). J Korean Med Sci  2017; 32: 221–230 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Yuan  J, Zou  XR, Han  SP  et al. ; on behalf of the C-STRIDE Study Group. Prevalence and risk factors for cardiovascular disease among chronic kidney disease patients: results from the Chinese cohort study of chronic kidney disease (C-STRIDE). BMC Nephrol  2017; 18: 23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Alencar de Pinho  N, Levin  A, Fukagawa  M  et al. ; International Network of Chronic Kidney Disease Cohort Studies (iNET-CKD). Considerable international variation exists in blood pressure control and antihypertensive prescription patterns in chronic kidney disease. Kidney Int  2019; 96: 983–994 [DOI] [PubMed] [Google Scholar]
  • 13. Dienemann  T, Fujii  N, Orlandi  P  et al.  International Network of Chronic Kidney Disease cohort studies (iNET-CKD): a global network of chronic kidney disease cohorts. BMC Nephrol  2016; 17: 121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Orlandi  PF, Huang  J, Fukagawa  M  et al. ; iNET-CKD Collaborators. A collaborative, individual-level analysis compared longitudinal outcomes across the International Network of Chronic Kidney Disease (iNETCKD) cohorts. Kidney Int  2019; 96: 1217–1233 [DOI] [PubMed] [Google Scholar]
  • 15. Kumar  V, Yadav  AK, Gang  S  et al.  Indian chronic kidney disease study: design and methods. Nephrology (Carlton)  2017; 22: 273–278 [DOI] [PubMed] [Google Scholar]
  • 16. Sumida  K, Nadkarni  GN, Grams  ME  et al. ; Chronic Kidney Disease Prognosis Consortium. Conversion of urine protein-creatinine ratio or urine dipstick protein to urine albumin-creatinine ratio for use in chronic kidney disease screening and prognosis: an individual participant-based meta-analysis. Ann Intern Med  2020; 173: 426–435 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. CensusInfo India. 2011. http://www.dataforall.org/dashboard/censusinfo/ (20 August 2021, date last accessed)
  • 18. CRIC Data View. https://shiny.pmacs.upenn.edu/CRIC_DataView/ (20 August 2021, date last accessed)
  • 19. Titze  S, Schmid  M, Kottgen  A  et al.  Disease burden and risk profile in referred patients with moderate chronic kidney disease: composition of the German Chronic Kidney Disease (GCKD) cohort. Nephrol Dial Transplant  2015; 30: 441–451 [DOI] [PubMed] [Google Scholar]
  • 20. Neugarten  J, Golestaneh  L.  Influence of sex on the progression of chronic kidney disease. Mayo Clin Proc  2019; 94: 1339–1356 [DOI] [PubMed] [Google Scholar]
  • 21. Rajapurkar  MM, John  GT, Kirpalani  AL  et al.  What do we know about chronic kidney disease in India: first report of the Indian CKD registry. BMC Nephrol  2012; 13: 10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Islam  SM, Purnat  TD, Phuong  NT  et al.  Non-communicable diseases (NCDs) in developing countries: a symposium report. Global Health  2014; 10: 81. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Orth  SR, Ogata  H, Ritz  E.  Smoking and the kidney. Nephrol Dial Transplant  2000; 15: 1509–1511 [DOI] [PubMed] [Google Scholar]
  • 24. Mohan  P, Lando  HA, Panneer  S.  Assessment of tobacco consumption and control in India. Indian J Clin Med  2018; 9:1179916118759289 [Google Scholar]
  • 25. Ricardo  AC, Anderson  CA, Yang  W  et al.  Healthy lifestyle and risk of kidney disease progression, atherosclerotic events, and death in CKD: findings from the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis  2015; 65: 412–424 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Hyun  YY, Lee  KB, Han  SH  et al.  Nutritional status in adults with predialysis chronic kidney disease: KNOW-CKD study. J Korean Med Sci  2017; 32: 257–263 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Wu  X, Yang  L, Wang  Y  et al.  Effects of combined aerobic and resistance exercise on renal function in adult patients with chronic kidney disease: a systematic review and meta-analysis. Clin Rehabil  2020; 34: 851–865 [DOI] [PubMed] [Google Scholar]
  • 28. Hsieh  CF, Huang  SL, Chen  CL  et al.  Increased risk of chronic kidney disease among users of non-prescribed Chinese herbal medicine in Taiwan. Prev Med  2012; 55: 155–159 [DOI] [PubMed] [Google Scholar]
  • 29. Lai  MN, Lai  JN, Chen  PC  et al.  Risks of kidney failure associated with consumption of herbal products containing Mu Tong or Fangchi: a population-based case-control study. Am J Kidney Dis  2010; 55: 507–518 [DOI] [PubMed] [Google Scholar]
  • 30. Chen  HY, Pan  HC, Chen  YC  et al.  Traditional Chinese medicine use is associated with lower end-stage renal disease and mortality rates among patients with diabetic nephropathy: a population-based cohort study. BMC Complement Altern Med  2019; 19: 81. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. Guo  JC, Pan  HC, Yeh  BY  et al.  Associations between using Chinese herbal medicine and long-term outcome among pre-dialysis diabetic nephropathy patients: a retrospective population-based cohort study. Front Pharmacol  2021; 12: 616522. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Heung  M, Steffick  DE, Zivin  K  et al.  Acute kidney injury recovery pattern and subsequent risk of CKD: an analysis of veterans health administration data. Am J Kidney Dis  2016; 67: 742–752 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. Lin  MY, Chiu  YW, Chang  JS  et al.  Association of prescribed Chinese herbal medicine use with risk of end-stage renal disease in patients with chronic kidney disease. Kidney Int  2015; 88: 1365–1373 [DOI] [PubMed] [Google Scholar]
  • 34. Tatapudi  RR, Rentala  S, Gullipalli  P  et al.  High prevalence of CKD of unknown etiology in Uddanam, India. Kidney Int Rep  2019; 4: 380–389 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35. Rajapakse  S, Shivanthan  MC, Selvarajah  M.  Chronic kidney disease of unknown etiology in Sri Lanka. Int J Occup Environ Health  2016; 22: 259–264 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36. Weiner  DE, McClean  MD, Kaufman  JS  et al.  The Central American epidemic of CKD. Clin J Am Soc Nephrol  2013; 8: 504–511 [DOI] [PubMed] [Google Scholar]
  • 37. O’Callaghan-Gordo  C, Shivashankar  R, Anand  S  et al.  Prevalence of and risk factors for chronic kidney disease of unknown aetiology in India: secondary data analysis of three population-based cross-sectional studies. BMJ Open  2019; 9: e023353. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38. Anupama  YJ, Uma  G.  Prevalence of chronic kidney disease among adults in a rural community in South India: results from the kidney disease screening (KIDS) project. Indian J Nephrol  2014; 24: 214–221 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. Modi  GK, Yadav  AK, Ghosh  A  et al.  Nonmedical factors and health-related quality of life in CKD in India. Clin J Am Soc Nephrol  2020; 15: 191–199 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

sfab149_Supplementary_Data

Articles from Clinical Kidney Journal are provided here courtesy of Oxford University Press

RESOURCES